SVR rates
| % (n/N) | In patients tested for IL28B allele | In all ADVANCE patients (N=1088) | |||
| CC (N=150) | CT (N=224) | TT (N=80) | Total (N=454) | ||
| T12PR* | 90 (45/50) | 71 (48/68) | 73 (16/22) | 78 (109/140) | 75 (271/363) |
| T8PR** | 84 (38/45) | 57 (43/76) | 59 (19/32) | 65 (100/153) | 69 (250/364) |
| PR | 64 (35/55) | 25 (20/80) | 23 (6/26) | 38 (61/161) | 44 (158/361) |
* T12PR = T+PR 12 weeks, then PR 12 or 36 weeks depending on eRVR status.
** T8PR = T+PR 8 weeks, then PR 16 or 40 weeks depending on eRVR status.